Drug Trial Radar · NCT03271021
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Jan 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,488
Actual
Start
Jul 17, 2017
Primary completion
Sep 4, 2018
Study completion Sep 4, 2018
Sponsor
- Lead sponsor
- Vyne Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
Conditions
- Acne Vulgaris
Interventions
FMX101Drug
FMX101, 4% minocycline foam
Vehicle FoamDrug
Vehicle Foam
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12.Time frame: 12 weeks
- Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From BaselineTime frame: 12 weeks
Locations
98 sites in 1 country. Site status is shown where the registry gives one.
Foamix Investigational Site #376
Phoenix, Arizona
Foamix Investigational Site #395
Tucson, Arizona
Foamix Investigational Site #315
Bryant, Arkansas
Foamix Investigational Site #340
Fort Smith, Arkansas
Foamix Investigational SIte #377
Little Rock, Arkansas
Foamix Investigational Site #366
Encino, California
Foamix Investigational Site #403
Los Angeles, California
Foamix Investigational Site #303
Murrieta, California
Foamix Investigational Site #369
Northridge, California
Foamix Investigational Site #387
Palm Springs, California
Foamix Investigational Site #393
Pasadena, California
Foamix Investigational Site #380
Poway, California
Foamix Investigational Site # 328
Sacramento, California
Foamix Investigational Site #313
San Diego, California
Foamix Investigational Site #336
San Luis Obispo, California
Foamix Investigational Site #309
Santa Ana, California
Foamix Investigational Site #325
Santa Monica, California
Foamix Investigational Site #375
Temecula, California
Foamix Investigational Site #381
Aventura, Florida
Foamix Investigational SIte #371
Boca Raton, Florida
Foamix Investigational Site #311
Boca Raton, Florida
Foamix Investigational Site #398
Brandon, Florida
Foamix Investigational Site #329
Clearwater, Florida
Foamix Investigational Site #378
Davie, Florida
Foamix Investigational Site #396
DeLand, Florida
Foamix Investigational Site #392
Doral, Florida
Foamix Investigational Site #318
Fort Myers, Florida
Foamix Investigational Site #401
Hialeah, Florida
Foamix Investigational Site #400
Hialeah, Florida
Foamix Investigational Site #383
Lake Worth, Florida
Foamix Investigational Site #397
Miami, Florida
Foamix Investigational Site #370
Miami, Florida
Foamix Investigational Site #346
Miami Lakes, Florida
Foamix Investigational Site #347
Miami Lakes, Florida
Foamix Investigational Site #306
North Miami Beach, Florida
Foamix Investigational Site #312
Ormond Beach, Florida
Foamix Investigational Site #362
South Miami, Florida
Foamix Investigational SIte #382
Tamarac, Florida
Foamix Investigational Site #399
Tampa, Florida
Foamix Investigational Site #385
Tampa, Florida
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.